Generic Medicine Info
Hypersensitivity to carboplatin or other platinum-containing compd (e.g. cisplatin). Patient w/ severe bone marrow depression or significant bleeding; bleeding tumours. Concomitant use w/ yellow fever vaccine.
Special Precautions
Renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause nausea, vomiting, vision abnormalities and ototoxicity, if affected, do not drive or operate machinery. Monitoring Parameters Determine haematologic nadir by wkly blood counts during initial courses. Closely monitor hepatic and renal function tests. Neurological function including hearing assessment should also be monitored.
Adverse Reactions
Bone marrow suppression (thrombocytopenia, neutropenia, leucopenia), anaemia; nausea, vomiting, abdominal pain, diarrhoea, constipation, mucous membrane disorder; decreased CrCl, blood Na, K, Ca, and Mg; increased blood urea, blood alkaline phosphatase, aspartate aminotransferase, abnormal LFTs; infections, resp disorder, interstitial lung disease, haemorrhage, ototoxicity; alopecia, skin disorder, musculoskeletal disorder, asthenia, urogenital disorder; peripheral neuropathies, paraesthesia, decreased osteotendinous reflexes, visual disturbances (including vision loss), sensory disturbances, dysgeusia.
Potentially Fatal: Anaphylactic-type reactions (e.g. facial oedema, dyspnoea, tachycardia, low BP, urticaria, anaphylactic shock, bronchospasm), CV events including cardiac failure, embolism and cerebrovascular accident.
Drug Interactions
Additive myelosuppressive effects w/ other myelosuppressive agents. Increased risk of nephrotoxicity and/or ototoxicity w/ aminoglycosides or diuretics. Excessive immunosuppression w/ risk of lymphoproliferation w/ ciclosporin. Increased risk of exacerbation of convulsions w/ phenytoin, fosphenytoin. Enhanced adverse/toxic effects of live attenuated vaccines.
ATC Classification
L01XA02 - carboplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on carboplatin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in